NCT07307274

A Study of SYNT-101 to Test Safety, Tolerability and Pharmacodynamics of SYNT-101 in Healthy and Overweight Adults

A Phase 1 Randomised, Double-blind, Placebo-controlled Single Ascending and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SYNT-101 in Healthy Adults and Healthy Adults Who Are Overweight or Have Obesity

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 64 (estimated)
• Sponsor: Syntis Bio · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

A Phase 1, single-center, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacodynamics of single and multiple dose regimens of SYNT-101 in healthy and overweight adults.

Conditions

• Healthy
• Overweight and Obese Adults

Interventions

Type	Name	Description
DRUG	SYNT101	Tablet
DRUG	Placebo	Placebo tablet to match SYNT101 in appearance.

Timeline

• Start date: 2026-01-05
• Primary completion: 2026-10-01
• Completion: 2026-12-31
• First posted: 2025-12-29
• Last updated: 2026-01-15

Locations

1 site across 1 country: Australia